| Name | Title | Contact Details |
|---|
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
Innovative, Anatomic Solutions
BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.
Brightstone specializes in creating a customized support program for young people needing help through mentoring. Brightstone uses an action oriented approach that creates learning opportunities through real life situations. Our participants move beyon...
Insertec is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.